Celsus Therapeutics PLC (ADR) (NASDAQ:CLTX) major shareholder Sabby Management, Llc acquired 16,203 shares of Celsus Therapeutics PLC stock in a transaction dated Thursday, March 27th. The shares were purchased at an average price of $6.66 per share, for a total transaction of $107,911.98. Celsus Therapeutics PLC (ADR) (NASDAQ:CLTX) stock performance was -5.24% in last session and finished the day at $6.15. Traded volume was 35.9K shares in the last session and the average volume of the stock remained 20.09K shares.

An increase in European and U.S. sales helped Reliv International Inc. (NASDAQ:RELV) raise profits by a small amount in the fourth quarter. The Chesterfield-based maker of nutritional supplements reported net income of $503,000, or 4 cents a share, compared to $437,000, or 3 cents, a year ago. Reliv International, Inc (NASDAQ:RELV) dropped -11.45 percent to $2.32 Tuesday on volume of 60.8K shares. The intra-day range of the stock was $2.25 to $2.68. Reliv International, Inc (NASDAQ:RELV) has a market capitalization of $29.38million.

Fate Therapeutics, Inc. (NASDAQ:FATE) saw a big move last session, as the company’s shares fell by nearly 14% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. Fate Therapeutics Inc (NASDAQ:FATE)’s stock on Apr 01, 2014 reported a decrease of -7.60% to the closing price of $9.00. Its fifty two weeks range is $4.30 -$13.55. The total market capitalization recorded $183.92million. The overall volume in the last trading session was 86.3K shares. In its share capital, FATE has 20.44million outstanding shares.

CorMedix Inc. (NYSEMKT:CRMD), a specialty pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of infectious diseases in both acute and chronic care settings, today announced that it will report 2013 financial results on Monday, March 31, 2014. The Company’s Chief Executive Officer, Randy Milby, will be hosting a conference call on Tuesday, April 1, 2014 at 9:00 a.m. ET to discuss the Company’s 2013 results. On Tuesday, shares of CorMedix Inc. (NYSEMKT:CRMD) dropped -5.18% to close the day at $2.38. Company monthly performance is recorded as -17.93%. CorMedix Inc. (NYSEMKT:CRMD) quarterly revenue growth is 103.42%.